<SEC-DOCUMENT>0001104659-21-135333.txt : 20211108
<SEC-HEADER>0001104659-21-135333.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108073256
ACCESSION NUMBER:		0001104659-21-135333
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20211105
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		211386528

	BUSINESS ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105
		BUSINESS PHONE:		(781) 788-8869

	MAIL ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2132125d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20211105">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_KPRX_eyegatepharma.com_20211105 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20211105_20211105 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001372514 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityCentralIndexKey">0001372514</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="kprx-20211105.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-11-05to2021-11-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-05</xbrli:startDate>
        <xbrli:endDate>2021-11-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-052021-11-05_dei_FormerAddressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-05</xbrli:startDate>
        <xbrli:endDate>2021-11-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_907_edei--DocumentType_c20211105__20211105_zZJbUsj1Toml"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO SECTION&#160;13 OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b><span id="xdx_904_edei--DocumentPeriodEndDate_c20211105__20211105_zQynIjMMbfee"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 5, 2021</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20211105__20211105_zkmiIXd9Tg64"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityRegistrantName">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20211105__20211105_z2buvDsdraw3"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><b><span id="xdx_909_edei--EntityFileNumber_c20211105__20211105_zhbVsnSaKUSh"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityFileNumber">001-36672</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 49%; text-align: center"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20211105__20211105_zS9GCiFjpn3f"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityTaxIdentificationNumber">98-0443284</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20211105__20211105_zRbWn2bQ2Zl"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressAddressLine1">1371 East 2100 South</ix:nonNumeric></span></b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine2_c20211105__20211105_z6v8DrPNm5Ye"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20211105__20211105_zFMWPjerqQma"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressCityOrTown">Salt Lake City</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20211105__20211105_zAKJ1iPCb2Td"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20211105__20211105_zFWgyJS8uYzl"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b>&#160;</b></p>
</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 49%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20211105__20211105_z4zpqJvmAQRd"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b></p></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90F_edei--CityAreaCode_c20211105__20211105_zTf9heO4TT9"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_900_edei--LocalPhoneNumber_c20211105__20211105_ziK5gFw0Csqe"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:LocalPhoneNumber">788-8869</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityInformationFormerLegalOrRegisteredName_c20211105__20211105_zIriwCcw3UWe"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:EntityInformationFormerLegalOrRegisteredName">EyeGate Pharmaceuticals, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20211105__20211105__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zQqqRc2j4fX1"><ix:nonNumeric contextRef="From2021-11-052021-11-05_dei_FormerAddressMember" name="dei:EntityAddressAddressLine1">271 Waverley Oaks Road</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20211105__20211105__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_z5AdlFz0Plmi"><ix:nonNumeric contextRef="From2021-11-052021-11-05_dei_FormerAddressMember" name="dei:EntityAddressAddressLine2">Suite 108</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20211105__20211105__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_z890bMxCn6u1"><ix:nonNumeric contextRef="From2021-11-052021-11-05_dei_FormerAddressMember" name="dei:EntityAddressCityOrTown">Waltham</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20211105__20211105__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zC3C7GCFU08h"><ix:nonNumeric contextRef="From2021-11-052021-11-05_dei_FormerAddressMember" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20211105__20211105__dei--EntityAddressesAddressTypeAxis__dei--FormerAddressMember_zzBODB0tA64j"><ix:nonNumeric contextRef="From2021-11-052021-11-05_dei_FormerAddressMember" name="dei:EntityAddressPostalZipCode">02452</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--WrittenCommunications_c20211105__20211105_znScmWBFyjT1"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Written communications pursuant to Rule&#160;425
under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20211105__20211105_zUsEKXLef7L"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12
under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20211105__20211105_zfen6Si88aZ7"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20211105__20211105_zE5yHhhBc9K5"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class:</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 23%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 43%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--Security12bTitle_c20211105__20211105_zV49f9z69Sc1"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:Security12bTitle">Common Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20211105__20211105_zWPexEg3EdT7"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" name="dei:TradingSymbol">KPRX</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_90A_edei--SecurityExchangeName_c20211105__20211105_zo83KkCPnffe"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20211105__20211105_zGtuzVzdkoL9"><ix:nonNumeric contextRef="From2021-11-05to2021-11-05" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 5, 2021, Kiora Pharmaceuticals, Inc. (formerly known as
EyeGate Pharmaceuticals, Inc.) (the &#8220;Company&#8221;) <span style="background-color: white">filed with the Secretary of State of
the State of Delaware a Certificate of Ownership and Merger, merging its wholly-owned Delaware subsidiary, </span>Kiora Pharmaceuticals,
Inc.<span style="background-color: white">, into the Company and amending the Company&#8217;s certificate of incorporation to change its
name to &#8220;</span>Kiora Pharmaceuticals, Inc.<span style="background-color: white">&#8221; effective November 8, 2021 (the &#8220;Name
Change&#8221;).&#160; </span>The Company also amended and restated its bylaws to reflect the change to the Company&#8217;s name (the &#8220;Bylaws
Amendment&#8221;). The Name Change and the Bylaws Amendment each became effective on November 8, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In connection
with the <span style="background-color: white">Name Change</span>, the Company&#8217;s common stock will trade on the NASDAQ Capital Market
under the new ticker symbol &#8220;KPRX&#8221;. The new ticker symbol will become effective at the open of the market on November 8, 2021.
<span style="background-color: white">The Name Change resulted in a change to the CUSIP number for the Company&#8217;s outstanding shares
of common stock. The new CUSIP number for such common stock is </span></span>49721T101<span style="background-color: white">. Outstanding
stock certificates for shares of common stock of the Company continue to be valid and need not be exchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">Copies of the Certificate of
Ownership and Merger, as filed with the Secretary of State of the State of Delaware, reflecting the Name Change amendment to the certificate
of incorporation, and the Bylaws Amendment, are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On November
8, 2021, the Company moved its headquarters to 1371 East 2100 South, Suite 200, Salt Lake City, Utah 84105. The Company&#8217;s telephone
number remains the same: </span>(781) 788-9043.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 8, 2021, the Company issued a press release announcing
the <span style="background-color: white">Name Change</span>, corporate rebranding initiative and launch of its new website,&#160;<span style="text-decoration: underline">www.kiorapharma.com</span>.&#160;
The press release is furnished as Exhibit 99.1 and incorporated herein by reference.&#160; <span style="background-color: white">The
Company&#8217;s investor relations information, including press releases and links to the Company&#8217;s SEC filings, will now be found
on this website. The Company&#8217;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and
amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended,
and the Company&#8217;s corporate governance documents, including the charters of the committees of the Company&#8217;s board of directors
and Code of Ethics and Business Conduct, are available on this website. Any amendment to or waivers of the Code of Ethics and Business
Conduct will be disclosed on this website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item 9.01.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Exhibits.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby files or furnishes, as applicable, the following
exhibits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><a href="tm2132125d1_ex3-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></a></td>
    <td style="text-align: justify"><a href="tm2132125d1_ex3-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certificate of Ownership and Merger, amending the Company&#8217;s Restated Certificate of Incorporation to change its name to &#8220;Kiora Pharmaceuticals, Inc.&#8221;, effective November 8, 2021</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2132125d1_ex3-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></a></td>
    <td style="text-align: justify"><a href="tm2132125d1_ex3-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Second Amended and Restated Bylaws of Kiora Pharmaceuticals, Inc., effective November 8, 2021</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2132125d1_ex99-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></a></td>
    <td style="text-align: justify"><a href="tm2132125d1_ex99-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Press Release of the Company, dated as of November 8, 2021</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><b>&#160;</b></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>KIORA PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding-left: 0.25in; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Brian M. Strem, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Brian M. Strem, Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">Date: November 8, 2021</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LboO/9ilQ0WcImOIt8VFKW7NSOt0j+Rb2m2IIRCSc74cIUZiSxtdIsNllaWQY1WXyiFkeENGc0XvSHb7GPzM8K6tY2Vcv/7AhDyDnpmNl8rfe2ejLRYxhPOJnE0iCaGMpws4HUTQ6QmZmy7QOK1KUKaAE1PNGp3idviQqzcZqto+6YxsNZkY5Dgc5A9EoYzgSI16ET8spGkiglFfgdgyPesu5mkdVbAusfJZdkD/HXwB4XRJHw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2132125d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Certificate
of Ownership and Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Merging</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Kiora
Pharmaceuticals,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>with
and into</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>EyeGate
Pharmaceuticals,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>November&nbsp;5</B></FONT>,&nbsp;<B>2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to Section&nbsp;253 of the Delaware General Corporation Law (the &ldquo;<B>DGCL</B>&rdquo;),&nbsp;</FONT><FONT STYLE="font-variant: small-caps">EyeGate
Pharmaceuticals,&nbsp;Inc.</FONT>, a Delaware corporation&nbsp;(the &ldquo;<B>Corporation</B>&rdquo;), does hereby certify to the following
information relating to the merger (the &ldquo;<B>Merger</B>&rdquo;) of&nbsp;<FONT STYLE="font-variant: small-caps">Kiora Pharmaceuticals,&nbsp;Inc.</FONT>,
a Delaware corporation&nbsp;(the &ldquo;<B>Subsidiary</B>&rdquo;), with and into the Corporation, with the Corporation remaining as the
surviving corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation was incorporated on December&nbsp;28, 2004, under and pursuant to the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Subsidiary was incorporated on October&nbsp;19, 2021, under and pursuant to the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation owns all of the outstanding shares of each class of capital stock of the Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Board of Directors of the Corporation, by resolutions duly adopted at a meeting held on October&nbsp;20, 2021 and attached hereto as&nbsp;<U>Exhibit&nbsp;A</U>,
determined to merge the Subsidiary with and into the Corporation and to change the Corporation&rsquo;s name to Kiora Pharmaceuticals,&nbsp;Inc.
pursuant to Section&nbsp;253 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation shall be the surviving corporation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Pursuant
to Section&nbsp;253(b)&nbsp;of the DGCL, the name of the Corporation shall be amended upon the effectiveness of the Merger to be &ldquo;<B>Kiora
Pharmaceuticals,&nbsp;Inc.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Restated Certificate of Incorporation of the Corporation, as in effect immediately prior to the Merger, shall be the Certificate of Incorporation
of the surviving corporation, except that Article&nbsp;I shall be amended to read in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&ldquo;The name of the corporation
is Kiora Pharmaceuticals,&nbsp;Inc. (the &ldquo;Corporation&rdquo;).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Certificate of Ownership and Merger and the Merger shall become effective on November&nbsp;8, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif">In
Witness Whereof</FONT>,&nbsp;the Corporation has caused this Certificate of Ownership and Merger to be signed by an authorized officer,
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: small-caps bold 10pt Times New Roman, Times, Serif">EyeGate Pharmaceuticals,&nbsp;Inc.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/&nbsp;Brian M. Strem, Ph.D.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Brian M. Strem, Ph.D.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYEGATE PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Resolutions
of the board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B><BR>
October&nbsp;20, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Subsidiary Merger and Name Change</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">WHEREAS:</TD><TD STYLE="text-align: justify">The Board has determined that it is in the best interests of EyeGate Pharmaceuticals,&nbsp;Inc. (the &ldquo;<U>Corporation</U>&rdquo;)
to change the name of the Corporation to Kiora Pharmaceuticals,&nbsp;Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">WHEREAS:</TD><TD STYLE="text-align: justify">The Corporation owns all of the issued and outstanding shares of capital stock of Kiora Pharmaceuticals,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Subsidiary</U>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif">WHEREAS:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif">T</FONT>he
Board has determined that it is in the best interests of the Corporation to merge the Subsidiary with and into the Corporation,&nbsp;and
then amend the Restated Certificate of Incorporation of the Corporation (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;) to change
the name of the Corporation to Kiora Pharmaceuticals,&nbsp;Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps">NOW, THEREFORE,
BE IT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif">RESOLVED:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif">T</FONT>hat
the Subsidiary be merged with and into the Corporation pursuant to Section&nbsp;253 of the Delaware General Corporation Law (the &ldquo;<U>Merger</U>&rdquo;),
so that the separate existence of the Subsidiary shall cease as soon as the Merger shall become effective, and the Corporation shall continue
as the surviving corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">RESOLVED:</TD><TD STYLE="text-align: justify">That each share of common stock of the Subsidiary, par value $0.01 per share, issued and outstanding immediately
prior to the effectiveness of the Merger shall automatically be cancelled and retired and shall cease to exist;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">RESOLVED:</TD><TD STYLE="text-align: justify">That the Certificate of Incorporation, as in effect immediately prior to the Merger, shall be the Certificate
of Incorporation of the surviving corporation, except that the First Article&nbsp;shall be amended to read in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;</FONT>The
name of the corporation is Kiora Pharmaceuticals,&nbsp;Inc. (the &ldquo;Corporation&rdquo;).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">RESOLVED:</TD><TD STYLE="text-align: justify">That&nbsp;that any of the Executive Chairman, President and Chief Executive Officer and the Chief Financial
Officer of the Corporation (collectively, the &ldquo;<U>Authorized Officers</U>&rdquo;)&nbsp;be, and each of them hereby is, authorized
to prepare and execute a Certificate of Ownership and Merger setting forth a copy of these resolutions, and to file the Certificate of
Ownership and Merger with the Secretary of State of Delaware and pay any fees related to such filing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in">RESOLVED:</TD><TD STYLE="text-align: justify">That each of the Authorized Officers be, and each of them hereby is, authorized and empowered to take
all such further actions and to execute, deliver and file all such further agreements, certificates, instruments and documents, in the
name and on behalf of the Corporation, and if requested or required, under its corporate seal duly attested by the Secretary; to pay or
cause to be paid all expenses; to take all such other actions as they or any one of them shall deem necessary, desirable, advisable or
appropriate to consummate, effectuate, carry out or further the transactions contemplated by and the intent and purposes of the foregoing
resolutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>tm2132125d1_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECOND
AMENDED AND RESTATED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>BYLAWS
OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>KIORA
Pharmaceuticals,&nbsp;Inc.,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EFFECTIVE:
NOVEMBER 8, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;I OFFICES
    AND RECORDS</FONT></TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; width: 12%; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; width: 80%; padding-bottom: 2pt">Delaware Office</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; width: 8%; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Other Offices</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;1.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Books and Records</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;II
    STOCKHOLDERS</FONT></TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Annual Meeting</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Special Meeting</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Place of Meeting</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Notice of Meeting</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Quorum and Adjournment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Proxies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Notice of Stockholder Business
    and Nominations</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Procedure for Election of Directors</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Inspectors of Elections</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Conduct of Meetings</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;2.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">No Consent of Stockholders in
    Lieu of Meeting</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;III
    BOARD OF DIRECTORS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">General Powers</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Number, Tenure and Qualifications</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Regular Meetings</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Special Meetings</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Action By Unanimous Consent
    of Directors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Notice</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Conference Telephone Meetings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Quorum</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vacancies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Committees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;3.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Removal</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE&nbsp;IV
    OFFICERS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Elected Officers</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section&nbsp;4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Election and Term of Office</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; width: 12%; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; width: 80%; text-align: left; padding-bottom: 2pt">Chairman of the Board</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; width: 8%; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">President and Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Secretary</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    4.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Treasurer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    4.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Removal</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    4.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Vacancies</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE
    V STOCK CERTIFICATES AND TRANSFERS</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Stock
    Certificates and Transfers</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE
    VI INDEMNIFICATION</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Right to Indemnification</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Right to Advancement of Expenses</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Right of Indemnitee to Bring Suit</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Non-Exclusivity
    of Rights</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Insurance</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Amendment of Rights</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    6.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Indemnification of Employees and Agents of the Corporation</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE
    VII MISCELLANEOUS PROVISIONS</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt">Fiscal Year</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Dividends</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Seal</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Waiver
    of Notice</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Audits</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Resignations</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Contracts</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    7.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt">Proxies</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: left; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ARTICLE
    VIII AMENDMENTS </FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Section
    8.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Amendments</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: right; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OFFICES AND RECORDS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delaware
Office</U>. The registered office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New
Castle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Other
Offices</U>. The Corporation may have such other offices, either within or without the State of Delaware, as the Board of Directors may
designate or as the business of the Corporation may from time to time require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.3</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Books
and Records</U>. The books and records of the Corporation may be kept at the Corporation&rsquo;s headquarters or at such other locations
within or without the State of Delaware as may from time to time be designated by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>STOCKHOLDERS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Annual
Meeting</U>. The annual meeting of the stockholders of the Corporation shall be held at such date, place and/or time as may be fixed by
resolution of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Special
Meeting</U>. Special meetings of stockholders of the Corporation may be called only by the Chairman of the Board or the President or by
the Board of Directors acting pursuant to a resolution adopted by a majority of the Whole Board. For purposes of these Second Amended
and Restated Bylaws, the term &ldquo;Whole Board&rdquo; shall mean the total number of authorized directors whether or not there exist
any vacancies in previously authorized directorships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Place
of Meeting</U>. The Board of Directors may designate the place of meeting for any meeting of the stockholders or the means of remote communications
by which any meeting shall be held. If no designation is made by the Board of Directors, the place of meeting shall be the principal office
of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
of Meeting</U>. Except as otherwise required by law, written, printed or electronic notice stating the place, if any, date and time of
the meeting, the means of remote communications, if any, by which the stockholders and proxy holders may be deemed to be present in person
and vote at such meeting, and in the case of a special meeting, the purposes for which the meeting is called shall be prepared and delivered
by the Corporation not less than ten (10)&nbsp;days nor more than sixty (60) days before the date of the meeting, either personally, by
mail, or in the case of stockholders who have consented to such delivery, by electronic transmission (as such term is defined in the General
Corporation Law of the State of Delaware (the &ldquo;GCL&rdquo;)), to each stockholder of record entitled to vote at such meeting. If
mailed, such notice shall be deemed to be delivered when deposited in the U.S. mail with postage thereon prepaid, addressed to the stockholder
at his address as it appears on the stock transfer books of the Corporation. Notice given by electronic transmission shall be effective
(A)&nbsp;if by facsimile, when faxed to a number where the stockholder has consented to receive notice; (B)&nbsp;if by electronic mail,
when mailed electronically to an electronic mail address at which the stockholder has consented to receive such notice; (C)&nbsp;if by
posting on an electronic network together with a separate notice of such posting, upon the later to occur of (1)&nbsp;the posting or (2)&nbsp;the
giving of separate notice of the posting; or (D)&nbsp;if by other form of electronic communication, when directed to the stockholder in
the manner consented to by the stockholder. Meetings may be held without notice if all stockholders entitled to vote are present (except
as otherwise provided by law), or if notice is waived by those not present. Any previously scheduled meeting of the stockholders may be
postponed and (unless the Corporation&rsquo;s Restated Certificate of Incorporation (the &ldquo;Certificate of Incorporation&rdquo;) otherwise
provides) any special meeting of the stockholders may be cancelled, by resolution of the Board of Directors upon public notice given prior
to the time previously scheduled for such meeting of stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.5</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Quorum
and Adjournment</U>. Except as otherwise provided by law or by the Certificate of Incorporation, the holders of a majority of the voting
power of the outstanding shares of the Corporation entitled to vote generally in the election of directors (the &ldquo;Voting Stock&rdquo;),
represented in person or by proxy, shall constitute a quorum at a meeting of stockholders, except that when specified business is to be
voted on by a class or series voting separately as a class or series, the holders of a majority of the voting power of the shares of such
class or series shall constitute a quorum for the transaction of such business for the purposes of taking action on such business. If
a quorum shall fail to attend any meeting, the chairman of the meeting may adjourn the meeting to another place, if any, date or time.
No notice of an adjourned meeting need be given if the time, place, if any, and the means of remote communication, if any, by which stockholders
and proxy holders may be deemed to be present and vote at such adjourned meeting are announced at the meeting at which the adjournment
is taken; provided such adjournment is for not more than thirty (30) days and further provided that no new record date is fixed for the
adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.6</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Proxies</U>.
At all meetings of stockholders, a stockholder may vote by proxy executed in writing by the stockholder or as may be permitted by law,
or by his duly authorized attorney-in-fact. Such proxy must be filed with the Secretary of the Corporation or his representative, or otherwise
delivered telephonically or electronically as set forth in the applicable proxy statement, at or before the time of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.7</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
of Stockholder Business and Nominations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Nominations
of persons for election to the Board of Directors and the proposal of business to be transacted by the stockholders may be made at an
annual meeting of stockholders (1)&nbsp;pursuant to the Corporation&rsquo;s notice with respect to such meeting, (2)&nbsp;by or at the
direction of the Board of Directors or (3)&nbsp;by any stockholder of record of the Corporation who was a stockholder of record at the
time of the giving of the notice provided for in the following paragraph, who is entitled to vote at the meeting and who has complied
with the notice procedures set forth in this Section&nbsp;2.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to paragraph (A)(3)&nbsp;of this
Section&nbsp;2.7, (1)&nbsp;the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (2)&nbsp;such
business must be a proper matter for stockholder action under the GCL, (3)&nbsp;if the stockholder, or the beneficial owner on whose behalf
any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in subclause
(c)(iii)&nbsp;of this paragraph, such stockholder or beneficial owner must, in the case of a proposal, have delivered prior to the meeting
a proxy statement and form of proxy to holders of at least the percentage of the Corporation&rsquo;s voting shares required under applicable
law to carry any such proposal, or, in the case of a nomination or nominations, have delivered prior to the meeting a proxy statement
and form of proxy to holders of a percentage of the Corporation&rsquo;s voting shares reasonably believed by such stockholder or beneficial
holder to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have
included in such materials the Solicitation Notice and (4)&nbsp;if no Solicitation Notice relating thereto has been timely provided pursuant
to this section, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies
sufficient to have required the delivery of such a Solicitation Notice under this section. To be timely, a stockholder&rsquo;s notice
shall be delivered to the Secretary at the principal executive offices of the Corporation not less than forty-five (45) or more than seventy-five
(75) days prior to the first anniversary (the &ldquo;Anniversary&rdquo;) of the date on which the Corporation first mailed its proxy materials
for the preceding year&rsquo;s annual meeting of stockholders; provided, however, that if no proxy materials were mailed by the Corporation
in connection with the preceding year&rsquo;s annual meeting, or if the date of the annual meeting is advanced more than thirty (30) days
prior to or delayed by more than thirty (30) days after the anniversary of the preceding year&rsquo;s annual meeting, notice by the stockholder
to be timely must be so delivered not later than the close of business on the later of (x)&nbsp;the 90th day prior to such annual meeting
or (y)&nbsp;the 10th day following the day on which public announcement of the date of such meeting is first made. Such stockholder&rsquo;s
notice shall set forth (a)&nbsp;as to each person whom the stockholder proposes to nominate for election or reelection as a director all
information relating to such person as would be required to be disclosed in solicitations of proxies for the election of such nominees
as directors pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and such
person&rsquo;s written consent to serve as a director if elected; (b)&nbsp;as to any other business that the stockholder proposes to bring
before the meeting, a brief description of such business, the reasons for conducting such business at the meeting and any material interest
in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and (c)&nbsp;as to the stockholder
giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (i)&nbsp;the name and address of
such stockholder, as they appear on the Corporation&rsquo;s books, and of such beneficial owner, (ii)&nbsp;the class and number of shares
of the Corporation that are owned beneficially and of record by such stockholder and such beneficial owner, and (iii)&nbsp;whether either
such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal,
at least the percentage of the Corporation&rsquo;s voting shares required under applicable law to carry the proposal or, in the case of
a nomination or nominations, a sufficient number of holders of the Corporation&rsquo;s voting shares to elect such nominee or nominees
(an affirmative statement of such intent, a &ldquo;Solicitation Notice&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in the second sentence of paragraph (B)&nbsp;of this Section&nbsp;2.7 to the contrary, in the event that the number of directors
to be elected to the Board of Directors is increased and there is no public announcement naming all of the nominees for director or specifying
the size of the increased Board of Directors made by the Corporation at least fifty-five (55) days prior to the Anniversary, a stockholder&rsquo;s
notice required by this Bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such
increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of
business on the 10th day following the day on which such public announcement is first made by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Only
persons nominated in accordance with the procedures set forth in this Section&nbsp;2.7 shall be eligible to serve as directors and only
such business shall be conducted at an annual meeting of stockholders as shall have been brought before the meeting in accordance with
the procedures set forth in this Section&nbsp;2.7. The chair of the meeting shall have the power and the duty to determine whether a nomination
or any business proposed to be brought before the meeting has been made in accordance with the procedures set forth in these Bylaws and,
if any proposed nomination or business is not in compliance with these Bylaws, to declare that such defective proposed business or nomination
shall not be presented for stockholder action at the meeting and shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Only
such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&rsquo;s
notice of meeting. Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which
directors are to be elected pursuant to the Corporation&rsquo;s notice of meeting (1)&nbsp;by or at the direction of the Board of Directors
or (2)&nbsp;by any stockholder of record of the Corporation who is a stockholder of record at the time of giving of notice provided for
in this paragraph, who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in this Section&nbsp;2.7.
Nominations by stockholders of persons for election to the Board of Directors may be made at such a special meeting of stockholders if
the stockholder&rsquo;s notice required by paragraph (B)&nbsp;of this Section&nbsp;2.7 shall be delivered to the Secretary at the principal
executive offices of the Corporation not later than the close of business on the later of the 90th day prior to such special meeting or
the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed
by the Board of Directors to be elected at such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of this Section&nbsp;2.7, &ldquo;public announcement&rdquo; shall mean disclosure in a press release reported by the Dow Jones
News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities
and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d)&nbsp;of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing provisions of this Section&nbsp;2.7, a stockholder shall also comply with all applicable requirements of the Exchange Act
and the rules&nbsp;and regulations thereunder with respect to matters set forth in this Section&nbsp;2.7. Nothing in this Section&nbsp;2.7
shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&rsquo;s proxy statement pursuant
to Rule&nbsp;14a-8 under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.8</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Procedure
for Election of Directors</U>. Election of directors at all meetings of the stockholders at which directors are to be elected shall be
by written ballot, and, except as otherwise set forth in the Certificate of Incorporation with respect to the right of the holders of
any series of Preferred Stock or any other series or class of stock to elect additional directors under specified circumstances, a plurality
of the votes cast thereat shall elect directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Except as otherwise provided by law, the Certificate
of Incorporation or these Bylaws, all matters other than the election of directors submitted to the stockholders at any meeting shall
be decided by the affirmative vote of a majority of the voting power of the outstanding Voting Stock present in person or represented
by proxy at the meeting and entitled to vote thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.9</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Inspectors
of Elections</U>. The Board of Directors by resolution may, and to the extent required by law, shall appoint one or more inspectors, which
inspector or inspectors may include individuals who serve the Corporation in other capacities, including, without limitation, as officers,
employees, agents or representatives of the Corporation, to act at the meeting and make a written report thereof. One or more persons
may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate has been appointed to
act, or if all inspectors or alternates who have been appointed are unable to act, at a meeting of stockholders, the chairman of the meeting
may, and to the extent required by law, shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging
his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to
the best of his or her ability. The inspectors shall have the duties prescribed by the GCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.10</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conduct
of Meetings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
President and Chief Executive Officer shall preside at all meetings of the stockholders. In the absence of the President and Chief Executive
Officer, the Chairman of the Board shall preside at a meeting of the stockholders. In the absence of both the President and Chief Executive
Officer and the Chairman of the Board, the Secretary shall preside at a meeting of the stockholders. In the anticipated absence of all
officers designated to preside over the meetings of stockholders, the Board of Directors may designate an individual to preside over a
meeting of the stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
chairman of the meeting shall fix and announce at the meeting the date and time of the opening and the closing of the polls for each matter
upon which the stockholders will vote at a meeting. The chairman shall have the power to adjourn the meeting to another place, if any,
date and time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board of Directors may, to the extent not prohibited by law, adopt by resolution such rules&nbsp;and regulations for the conduct of the
meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules&nbsp;and regulations as adopted
by the Board of Directors, the chairman of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations
and procedures and to do all such acts as, in the judgment of such chairman, are appropriate for the proper conduct of the meeting. Such
rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairman of the meeting, may to the extent
not prohibited by law include, without limitation, the following: (i)&nbsp;the establishment of an agenda or order of business for the
meeting; (ii)&nbsp;rules&nbsp;and procedures for maintaining order at the meeting and the safety of those present; (iii)&nbsp;limitations
on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies
or such other persons as the chairman of the meeting shall determine; (iv)&nbsp;restrictions on entry to the meeting after the time fixed
for the commencement thereof and (v)&nbsp;limitations on the time allotted to questions or comments by participants. Unless, and to the
extent, determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held
in accordance with the rules&nbsp;of parliamentary procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.11</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Consent of Stockholders in Lieu of Meeting</U>. Subject to the rights of the holders of any series of Preferred Stock, any action required
or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders
of the Corporation and may not be effected by any consent in writing by such stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>BOARD OF DIRECTORS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>General
Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. In addition
to the powers and authority expressly conferred upon them by statute or by the Certificate of Incorporation or by these Bylaws, the directors
are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Number,
Tenure and Qualifications</U>. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under
specified circumstances, the number of directors shall be fixed from time to time exclusively by the Board of Directors pursuant to a
resolution adopted by a majority of the Whole Board. The directors, other than those who may be elected by the holders of any series of
Preferred Stock under specified circumstances, shall be divided into three classes pursuant to the Certificate of Incorporation. At each
annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office
to expire at the third succeeding annual meeting of stockholders after their election. The foregoing notwithstanding, each director shall
serve until such director&rsquo;s successor shall have been duly elected and qualified, or until such director&rsquo;s prior death, resignation,
retirement, disqualification or other removal. The Board of Directors is authorized to assign members of the Board of Directors already
in office to such classes as it may determine at the time the classification of the Board of Directors becomes effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Regular
Meetings</U>. The Board of Directors may, by resolution, provide the time and place for the holding of regular meetings of the Board of
Directors. A notice of each regular meeting shall not be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Special
Meetings</U>. Special meetings of the Board of Directors shall be called at the request of the Chairman of the Board, the Chief Executive
Officer or a majority of the Board of Directors. The person or persons authorized to call special meetings of the Board of Directors may
fix the place and time of the meetings, and the writing or transmission shall be filed with the minutes of proceedings of the Board of
Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Action
By Unanimous Consent of Directors</U>. The Board of Directors may take action without the necessity of a meeting by unanimous consent
of directors. Such consent may be in writing or given by electronic transmission, as such term is defined in the GCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice</U>.
Notice of any special meeting shall be given to each director at his business or residence in writing, or by telegram, facsimile transmission,
telephone communication or electronic transmission (provided, with respect to electronic transmission, that the director has consented
to receive the form of transmission at the address to which it is directed). If mailed, such notice shall be deemed adequately delivered
when deposited in the United States mails so addressed, with postage thereon prepaid, at least five (5)&nbsp;days before such meeting.
If by telegram, such notice shall be deemed adequately delivered when the telegram is delivered to the telegraph company at least twenty-four
(24) hours before such meeting. If by facsimile transmission or other electronic transmission, such notice shall be transmitted at least
twenty-four (24) hours before such meeting. If by telephone, the notice shall be given at least twelve (12) hours prior to the time set
for the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors
need be specified in the notice of such meeting, except for amendments to these Bylaws as provided under Section&nbsp;8.1 of Article&nbsp;VIII
hereof. A meeting may be held at any time without notice if all the directors are present (except as otherwise provided by law) or if
those not present waive notice of the meeting in writing or by electronic transmission, either before or after such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conference
Telephone Meetings</U>. Members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board of Directors
or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in
the meeting can hear each other, and such participation in a meeting shall constitute presence in person at such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.8</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Quorum</U>.
A whole number of directors equal to at least a majority of the Whole Board shall constitute a quorum for the transaction of business,
but if at any meeting of the Board of Directors there shall be less than a quorum present, a majority of the directors present may adjourn
the meeting from time to time without further notice. The act of the majority of the directors present at a meeting at which a quorum
is present shall be the act of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.9</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Vacancies</U>.
Subject to the rights of the holders of any series of Preferred Stock then outstanding, newly created directorships resulting from any
increase in the authorized number of directors or any vacancies in the Board of Directors resulting from death, resignation, retirement,
disqualification, removal from office or other cause shall, unless otherwise provided by law or by resolution of the Board of Directors,
be filled only by a majority vote of the directors then in office, though less than a quorum (and not by stockholders), and directors
so chosen shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which
they have been chosen expires or until such director&rsquo;s successor has been duly elected and qualified. No decrease in the authorized
number of directors shall shorten the term of any incumbent director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.10</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Committees</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation.
The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified
member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof
present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another
member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the
extent permitted by law and to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers
and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of
the Corporation to be affixed to all papers which may require it; provided, however, that no committee shall have power or authority in
reference to the following matters: (1)&nbsp;approving, adopting or recommending to stockholders any action or matter required by law
to be submitted to stockholders for approval or (2)&nbsp;adopting, amending or repealing any bylaw.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Unless
the Board of Directors otherwise provides, each committee designated by the Board of Directors may make, alter and repeal rules&nbsp;for
the conduct of its business. In the absence of such rules&nbsp;each committee shall conduct its business in the same manner as the Board
of Directors conducts its business pursuant to these Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.11</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Removal</U>.
Subject to the rights of the holders of any series of Preferred Stock then outstanding, any director, or the entire Board of Directors,
may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least two-thirds of the
voting power of all of the then-outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors,
voting together as a single class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OFFICERS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Elected
Officers</U>. The elected officers of the Corporation shall be a Chairman of the Board, a President, a Secretary, a Treasurer, and such
other officers as the Board of Directors from time to time may deem proper. The Chairman of the Board shall be chosen from the directors.
All officers chosen by the Board of Directors shall each have such powers and duties as generally pertain to their respective offices,
subject to the specific provisions of this Article&nbsp;IV. Such officers shall also have powers and duties as from time to time may be
conferred by the Board of Directors or by any committee thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Election
and Term of Office</U>. The elected officers of the Corporation shall be elected annually by the Board of Directors at the regular meeting
of the Board of Directors held after each annual meeting of the stockholders. If the election of officers shall not be held at such meeting,
such election shall be held as soon thereafter as convenient. Subject to Section&nbsp;4.7 of these Bylaws, each officer shall hold office
until his successor shall have been duly elected and shall have qualified or until his death or until he shall resign.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Chairman
of the Board</U>. The Chairman of the Board shall preside at all meetings of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.4</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>President
and Chief Executive Officer</U>. The President and Chief Executive Officer shall be the general manager of the Corporation, subject to
the control of the Board of Directors, and as such shall, subject to Section&nbsp;2.10(A)&nbsp;hereof, preside at all meetings of stockholders,
shall have general supervision of the affairs of the Corporation, shall sign or countersign or authorize another officer to sign all certificates,
contracts, and other instruments of the Corporation as authorized by the Board of Directors, shall make reports to the Board of Directors
and stockholders, and shall perform all such other duties as are incident to such office or are properly required by the Board of Directors.
If the Board of Directors creates the office of Chief Executive Officer as a separate office from President, the President shall be the
chief operating officer of the corporation and shall be subject to the general supervision, direction, and control of the Chief Executive
Officer unless the Board of Directors provides otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.5</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Secretary</U>.
The Secretary shall give, or cause to be given, notice of all meetings of stockholders and directors and all other notices required by
law or by these Bylaws, and in case of his absence or refusal or neglect so to do, any such notice may be given by any person thereunto
directed by the Chairman of the Board or the President, or by the Board of Directors, upon whose request the meeting is called as provided
in these Bylaws. The Secretary shall record all the proceedings of the meetings of the Board of Directors, any committees thereof and
the stockholders of the Corporation in a book to be kept for that purpose, and shall perform such other duties as may be assigned to the
Secretary by the Board of Directors, the Chairman of the Board or the President. The Secretary shall have custody of the seal of the Corporation
and shall affix the same to all instruments requiring it, when authorized by the Board of Directors, the Chairman of the Board or the
President, and attest to the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.6</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Treasurer</U>.
The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate receipts and disbursements
in books belonging to the Corporation. The Treasurer shall deposit all moneys and other valuables in the name and to the credit of the
Corporation in such depositaries as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the Corporation
as may be ordered by the Board of Directors the Chairman of the Board, or the President, taking proper vouchers for such disbursements.
The Treasurer shall render to the Chairman of the Board, the President and the Board of Directors, whenever requested, an account of all
his transactions as Treasurer and of the financial condition of the Corporation. If required by the Board of Directors, the Treasurer
shall give the Corporation a bond for the faithful discharge of his duties in such amount and with such surety as the Board of Directors
shall prescribe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.7</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Removal</U>.
Any officer elected by the Board of Directors may be removed by the Board of Directors at any time, with or without cause. No elected
officer shall have any contractual rights against the Corporation for compensation by virtue of such election beyond the date of the election
of his successor, his death, his resignation or his removal, whichever event shall first occur, except as otherwise provided in an employment
contract or an employee plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.8</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Vacancies</U>.
A newly created office and a vacancy in any office because of death, resignation, or removal may be filled by the Board of Directors for
the unexpired portion of the term at any meeting of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>STOCK CERTIFICATES AND TRANSFERS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Stock
Certificates and Transfers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Unless
the Board of Directors has determined by resolution that some or all of any or all classes or series of stock shall be uncertificated
shares, the interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock in such form as the
appropriate officers of the Corporation may from time to time prescribe. The shares of the stock of the Corporation shall be transferred
on the books of the Corporation by the holder thereof in person or by his attorney, upon surrender for cancellation of certificates for
the same number of shares, with an assignment and power of transfer endorsed thereon or attached thereto, duly executed, and with such
proof of the authenticity of the signature as the Corporation or its agents may reasonably require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Every
holder of stock represented by certificates shall be entitled to have a certificate signed, countersigned and registered in such manner
as the Board of Directors may by resolution prescribe, which resolution may permit all or any of the signatures on such certificates to
be in facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate
has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with
the same effect as if he were such officer, transfer agent or registrar at the date of issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>INDEMNIFICATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Right
to Indemnification</U>. Each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any
action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &ldquo;proceeding&rdquo;), by reason
of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or
was serving at the request of the Corporation as a director, officer, employee, trustee or agent of another corporation or of a partnership,
joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an &ldquo;indemnitee&rdquo;),
where the basis of such proceeding is alleged action in an official capacity as a director, officer, employee, trustee or agent or in
any other capacity while serving as a director, officer, trustee or agent, shall be indemnified and held harmless by the Corporation to
the fullest extent authorized by the GCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only
to the extent that such amendment permits the Corporation to provide broader indemnification rights than permitted prior thereto), against
all expense, liability and loss (including attorneys&rsquo; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in
settlement) reasonably incurred or suffered by such indemnitee in connection therewith and such indemnification shall continue as to an
indemnitee who has ceased to be a director, officer, employee, trustee or agent and shall inure to the benefit of the indemnitee&rsquo;s
heirs, executors and administrators; provided, however, that, except as provided in Section&nbsp;6.3 hereof with respect to proceedings
to enforce rights to indemnification, the Corporation shall indemnify any such indemnitee in connection with a proceeding (or part thereof)
initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Right
to Advancement of Expenses</U>. The right to indemnification conferred in Section&nbsp;6.1 shall include the right to be paid by the Corporation
the expenses (including attorney&rsquo;s fees) incurred in defending any proceeding for which such right to indemnification is applicable
in advance of its final disposition (hereinafter an &ldquo;advancement of expenses&rdquo;); provided, however, that, if the GCL requires,
an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer (and not in any other capacity in
which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made
only upon delivery to the Corporation of an undertaking (hereinafter an &ldquo;undertaking&rdquo;), by or on behalf of such indemnitee,
to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right
to appeal (hereinafter a &ldquo;final adjudication&rdquo;) that such indemnitee is not entitled to be indemnified for such expenses under
this Section&nbsp;or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Right
of Indemnitee to Bring Suit</U>. The rights to indemnification and to the advancement of expenses conferred in Section&nbsp;6.1 and Section&nbsp;6.2,
respectively, shall be contract rights. If a claim under Section&nbsp;6.1 or Section&nbsp;6.2 is not paid in full by the Corporation within
sixty days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in
which case the applicable period shall be twenty days, the indemnitee may at any time thereafter bring suit against the Corporation to
recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to
recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense
of prosecuting or defending such suit. In (A)&nbsp;any suit brought by the indemnitee to enforce a right to indemnification hereunder
(but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (B)&nbsp;in
any suit by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking the Corporation shall be entitled
to recover such expenses upon a final adjudication that, the indemnitee has not met any applicable standard for indemnification set forth
in the GCL. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders)
to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances
because the indemnitee has met the applicable standard of conduct set forth in the GCL, nor an actual determination by the Corporation
(including its Board of Directors, independent legal counsel, or its stockholders) that the indemnitee has not met such applicable standard
of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit
brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification or to
an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking,
the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Section&nbsp;or
otherwise shall be on the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Non-Exclusivity
of Rights</U>. The rights to indemnification and to the advancement of expenses conferred in this Article&nbsp;VI shall not be exclusive
of any other right which any person may have or hereafter acquire under the Certificate of Incorporation, these Second Amended and Restated
Bylaws, or any statute, agreement, vote of stockholders or disinterested directors or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.5</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation
or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the
Corporation would have the power to indemnify such person against such expense, liability or loss under the GCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.6</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment
of Rights</U>. Any amendment, alteration or repeal of this Article&nbsp;VI that adversely affects any right of an indemnitee or its successors
shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence or alleged
occurrence of any action or omission to act that took place prior to such amendment or repeal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.7</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Employees and Agents of the Corporation</U>. The Corporation may, to the extent authorized from time to time by the Board of Directors,
grant rights to indemnification, and to the advancement of expenses, to any employee or agent of the Corporation to the fullest extent
of the provisions of this Section&nbsp;with respect to the indemnification and advancement of expenses of directors and officers of the
Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>MISCELLANEOUS PROVISIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fiscal
Year</U>. The fiscal year of the Corporation shall begin on the first day of January&nbsp;and end on the thirty-first day of December&nbsp;of
each year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Dividends</U>.
The Board of Directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and
upon the terms and conditions provided by law and its Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Seal</U>.
The corporate seal shall have inscribed the name of the Corporation thereon and shall be in such form as may be approved from time to
time by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Waiver
of Notice</U>. Whenever any notice is required to be given to any stockholder or director of the Corporation under the provisions of the
GCL, the Certificate of Incorporation or the Bylaws, a waiver thereof in writing, signed by the person or persons entitled to such notice,
or a waiver by electronic transmission, whether before or after the time of the event for which notice is to be given, shall be deemed
equivalent to the giving of such notice. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of
the stockholders or the Board of Directors need be specified in any waiver of notice of such meeting. Attendance of a person at a meeting
shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at
the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Audits</U>.
The accounts, books and records of the Corporation shall be audited upon the conclusion of each fiscal year by an independent certified
public accountant selected by the Board of Directors, and it shall be the duty of the Board of Directors to cause such audit to be made
annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.6</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Resignations</U>.
Any director or any officer, whether elected or appointed, may resign at any time by serving written notice of such resignation on the
Chairman of the Board, the Chief Executive Officer or the Secretary, or by submitting such resignation by electronic transmission (as
such term is defined in the GCL), and such resignation shall be deemed to be effective as of the close of business on the date said notice
is received by the Chairman of the Board, the Chief Executive Officer, or the Secretary or at such later date as is stated therein. No
formal action shall be required of the Board of Directors or the stockholders to make any such resignation effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.7</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Contracts</U>.
Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, any contracts or other instruments may be executed
and delivered in the name and on the behalf of the Corporation by such officer or officers of the Corporation as the Board of Directors
may from time to time direct. Such authority may be general or confined to specific instances as the Board of Directors may determine.
The Chairman of the Board, the Chief Executive Officer, the President or any Vice President may execute bonds, contracts, deeds, leases
and other instruments to be made or executed for or on behalf of the Corporation. Subject to any restrictions imposed by the Board of
Directors or the Chairman of the Board, the Chief Executive Officer, the President or any Vice President of the Corporation may delegate
contractual powers to others under his jurisdiction, it being understood, however, that any such delegation of power shall not relieve
such officer of responsibility with respect to the exercise of such delegated power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.8</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Proxies</U>.
Unless otherwise provided by resolution adopted by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, the
President or any Vice President may from time to time appoint any attorney or attorneys or agent or agents of the Corporation, in the
name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other
securities in any other corporation or other entity, any of whose stock or other securities may be held by the Corporation, at meetings
of the holders of the stock and other securities of such other corporation or other entity, or to consent in writing, in the name of the
Corporation as such holder, to any action by such other corporation or other entity, and may instruct the person or persons so appointed
as to the manner of casting such votes or giving such consent, and may execute or cause to be executed in the name and on behalf of the
Corporation and under its corporate seal or otherwise, all such written proxies or other instruments as he may deem necessary or proper
in the premises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VIII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>AMENDMENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendments</U>.
Subject to the provisions of the Certificate of Incorporation (including the rights of the holders of any series of Preferred Stock then
outstanding), these Bylaws may be adopted, amended or repealed at any meeting of the Board of Directors by a resolution adopted by a majority
of the Whole Board, provided notice of the proposed change was given in the notice of the meeting in a notice given no less than twenty-four
(24) hours prior to the meeting. Subject to the provisions of the Certificate of Incorporation (including the rights of the holders of
any series of Preferred Stock then outstanding), the stockholders shall also have power to adopt, amend or repeal these Bylaws, provided
that notice of the proposed change was given in the notice of the meeting and provided further that, in addition to any vote of the holders
of any class or series of stock of the Corporation required by law or by the Certificate of Incorporation (including the rights of the
holders of any series of Preferred Stock then outstanding), the affirmative vote of the holders of at least two-thirds of the voting power
of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors,
voting together as a single class, shall be required to adopt, amend or repeal any provision of these Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm2132125d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EyeGate is Now Kiora Pharmaceuticals; Provides
Update on Company&rsquo;s</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sharpened Clinical Development Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SALT LAKE CITY, UT, November&nbsp;8, 2021 &ndash; Kiora Pharmaceuticals,&nbsp;Inc.
(NASDAQ: KPRX), (&ldquo;Kiora&rdquo; or the &ldquo;Company&rdquo;) is the new name of EyeGate Pharmaceuticals,&nbsp;Inc. (NASDAQ: EYEG).
Kiora will trade on the Nasdaq Capital Market under the ticker symbol &quot;KPRX&quot; and CUSIP number 49721T101. The new brand reflects
the Company&rsquo;s aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential
to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company&rsquo;s newly revamped clinical
development strategy is available in the Investors section of the Company&rsquo;s new website at <U>www.kiorapharma.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The rebranding reflects our sharpened focus on developing novel
ophthalmic therapeutics,&rdquo; said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. &quot;Our small molecule for
Retinitis Pigmentosa could offer a revolutionary treatment for a rare disease with a potentially expedited path to market. We&rsquo;ll
continue planned development of our mid and later stage clinical candidates in anterior segment eye diseases and explore partnering opportunities
of promising systemic indications outside our core focus.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Expanded Pipeline and Milestones</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kiora&rsquo;s pipeline now consists of three assets in early to late-stage
development for both common and rare eye diseases. The company anticipates achieving several milestones for these programs that will drive
value in the organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><B>KIO-101</B>, previously known as PP-001, is a next-generation small molecule inhibitor of Dihydroorotate Dehydrogenase (&ldquo;DHODH&rdquo;).
It has demonstrated picomolar potency with a validated mechanism (blocks T-cell proliferation) that may offer greater safety and tolerability
than DHODH inhibitors currently on the market. Anticipated milestones include:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Report topline data in fourth quarter of 2021 on a Ph1/2a safety, PK and exploratory ocular surface inflammation (dry eye) trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Explore licensing opportunities for non-core indications.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><B>KIO-301</B>, previously known as B-203, is a light-sensitive small molecule that acts as a reversible &lsquo;photoswitch&rsquo;,
specifically designed to restore the eyes&rsquo; ability to perceive and interpret light in visually impaired patients. KIO-301 selectively
enters specific retinal ganglion cells (those downstream of degenerated rods and cones) and converts them into light sensing cells, capable
of signaling the brain as to the presence or absence of light. Anticipated milestones include:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Initiate a Phase 1b clinical trial in the third quarter of 2022 in patients with later-stage Retinitis Pigmentosa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Apply for orphan drug designation in the U.S. in the first quarter of 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Further develop the platform for use in patients with Geographic Atrophy, the later stages of Age-Related Macular Degeneration (dry
AMD).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><B>KIO-201</B>, previously known as Ocular Bandage Gel or &ldquo;OBG&rdquo;, is a modified form of the natural polymer hyaluronic
acid designed to accelerate ocular surface wound healing. Kiora will be discussing the Phase 3b readiness of KIO-201 for patients undergoing
photorefractive keratectomy (&ldquo;PRK&rdquo;) surgery for corneal wound repair with the FDA, whilst performing an additional exploratory
phase 2 clinical trial in patients with persistent corneal epithelial defects. Anticipated milestones include:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Pre-IND meeting with the FDA in the first quarter of 2022 to confirm Phase 3b readiness in PRK surgery.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD>Report topline proof of concept, exploratory phase 2 clinical trial data in persistent epithelial defect patients in the third quarter
of 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Kiora</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kiora
is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases. KIO-301
is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration.
KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (&ldquo;DHODH&rdquo;)
with best-in-class picomolar potency and a validated immune modulating mechanism (T cell proliferation inhibition) designed to overcome
the off-target side effects and safety issues associated with DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified
form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. For more information, please visit <U>www.kiorapharma.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of the statements in this press release are &ldquo;forward-looking&rdquo;
and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &ldquo;forward-looking&rdquo;
statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing
approval efforts pertaining to Kiora&rsquo;s products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such
approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that
may cause results to differ materially from the statements set forth in this press release, including, among other things, market and
other conditions and certain risk factors described under the heading &ldquo;Risk Factors&rdquo; contained in Kiora&rsquo;s Annual Report
on Form&nbsp;10-K filed with the SEC on March&nbsp;25, 2021 or described in Kiora&rsquo;s other public filings. Kiora&rsquo;s results
may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only
as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions
to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances
on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corey Davis, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(212) 915-2577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">cdavis@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>kprx-20211105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOMabOdzZR++YkxtmB+bamqXyIlzgZCQyAXIleG4W8A -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20211105" elementFormDefault="qualified" targetNamespace="http://eyegatepharma.com/20211105">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://eyegatepharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20211105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20211105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20211105_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>kprx-20211105_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://eyegatepharma.com/role/Cover" xlink:href="kprx-20211105.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://eyegatepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>kprx-20211105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_FormerAddressMember" xlink:to="dei_FormerAddressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_FormerAddressMember_lbl" xml:lang="en-US">Former Address [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>kprx-20211105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://eyegatepharma.com/role/Cover" xlink:href="kprx-20211105.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://eyegatepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_FormerAddressMember" xlink:label="loc_deiFormerAddressMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiFormerAddressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm2132125d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20211105.xsd" xlink:type="simple"/>
    <context id="From2021-11-05to2021-11-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2021-11-05</startDate>
            <endDate>2021-11-05</endDate>
        </period>
    </context>
    <context id="From2021-11-052021-11-05_dei_FormerAddressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-05</startDate>
            <endDate>2021-11-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-11-05to2021-11-05">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-11-05to2021-11-05">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-11-05to2021-11-05">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2021-11-05to2021-11-05">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-11-05to2021-11-05">2021-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-11-05to2021-11-05">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-11-05to2021-11-05">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-11-05to2021-11-05">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-11-05to2021-11-05">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-11-05to2021-11-05">1371 East 2100 South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-11-05to2021-11-05">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-11-05to2021-11-05">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-11-05to2021-11-05">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-05to2021-11-05">84105</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-05to2021-11-05">84105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-11-05to2021-11-05">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-11-05to2021-11-05">788-8869</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName contextRef="From2021-11-05to2021-11-05">EyeGate Pharmaceuticals, Inc.</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:EntityAddressAddressLine1 contextRef="From2021-11-052021-11-05_dei_FormerAddressMember">271 Waverley Oaks Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-11-052021-11-05_dei_FormerAddressMember">Suite 108</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-11-052021-11-05_dei_FormerAddressMember">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-11-052021-11-05_dei_FormerAddressMember">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-052021-11-05_dei_FormerAddressMember">02452</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications contextRef="From2021-11-05to2021-11-05">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-11-05to2021-11-05">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-11-05to2021-11-05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-11-05to2021-11-05">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-11-05to2021-11-05">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-11-05to2021-11-05">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-11-05to2021-11-05">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-11-05to2021-11-05">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140386356737304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1371 East 2100 South<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-8869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">EyeGate Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">271 Waverley Oaks Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MVEX W\^E-/L3NZ^8;POW_@502P,$%     @ &SQH4Y^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !L\:%.2WT*1*P4  "(6   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  ;/&A3GZ ;\+$"  #B#   #0              @ %M#0  >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !L\:%.7BKL<P    !,"   +
M  "  4D0  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !L\:%.JQ"(6,P$  "("
M   /              "  3(1  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  ;/&A3)!Z;HJT   #X 0  &@              @ &2$@  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  ;/&A399!YDAD!  #/ P
M$P              @ %W$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #!%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2132125d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2132125d1_8k.htm">tm2132125d1_8k.htm</File>
    <File>kprx-20211105.xsd</File>
    <File>kprx-20211105_def.xml</File>
    <File>kprx-20211105_lab.xml</File>
    <File>kprx-20211105_pre.xml</File>
    <File>tm2132125d1_ex3-1.htm</File>
    <File>tm2132125d1_ex3-2.htm</File>
    <File>tm2132125d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2132125d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 2,
   "dts": {
    "definitionLink": {
     "local": [
      "kprx-20211105_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2132125d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20211105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20211105_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20211105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 1,
   "nsprefix": "KPRX",
   "nsuri": "http://eyegatepharma.com/20211105",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2132125d1_8k.htm",
      "contextRef": "From2021-11-05to2021-11-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2132125d1_8k.htm",
      "contextRef": "From2021-11-05to2021-11-05",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 1,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r11",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r12": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r17": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r20": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-21-135333-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-135333-xbrl.zip
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M$/QZ"ZP&LB5^;^_;YKJW]??;HV !, 7<QI<ZI(5!6KZ^2T!+N?H>K(XI\TN
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MB![H;0X<'D8 -H3'!@=][DH>+'N4#"Q$:N1H";_9!</X.>&P@:5380S]J:+
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M9B78G<.&T!:P!X" ]L8X:.N:.J" X[#FP7!7P#GXN %FPG<-(2C)KC)@^OB
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M\O5,VAW>1<4 %63^ 1\VXZ630"JP@.(+@I"#^9Y\.F"Z&6&Z(H30M.CD?,>
M3QLK#L"CE>@Q*XF@!I[NBK19F97XFU:MX9]0YH%Y'.%,S^6!-X_ ^5-3VUN
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MS+- ?M></,3LI7O,'S$,"==_T(&"]T2K[H2MNB-LL85O>.-2=J.7);:WJ$^
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M2S[802N[_+X'9 J.,?:C!JUM'P G)P1M7"CRNY#5BBD$BLM[0LI=LTYV&;)
M,=5.@$M7+_*HF<,&CF057L"6VV(= Q<@(@%SP"\U7J\+:D_2J8<;Z9YSA9>&
M#AJ&4H W@VO   F,'OG@L4)#Z_9$YMJA$J4XTCAELA.X.BUIH!*R\#0$FV^%
MV%0K63V*<:58Y<+Q,!2*+;UES*V>"?-%9$;Q/)D(2[D4_'8F!3^FX,K]!"GW
M[?(I]X?+?S?P[U78/V"!?^?B_U!+ P04    "  ;/&A3D"ET#2<_  "QQ $
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M%_I63N@!W4&/V[[9=&\S%8SQM/9P0RDK73'\X"D!:V^^"_H!$<^6@6\9N,_
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ME(T HBA+#E%XLQ)KO4KQ#PHI[GT86'$2-SS9 YTZ,5:IFL;D]\XN,5;!TJ3
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M*9$'#.,5U2V!!)2&7UC'PMCH.E6X-3.2Y+I7?6XE/>P29?8;K F>J-7*0T(
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MX9BC)@N)9T0)AB'&WN)96Q\ '"!K?/92$Z?81)Q+V^%\)9,IO@+N10TQ]*U
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M'%%9:_%3\ %/^S&HD*]75R%O3Y_[;O=H_\]?\#_^??K;AU_^/U!+ P04
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M[+U!2L>30*Z$O"V7MH OD7%,GAM;E*0.2FA8-;<FA3?BF5NX0I&]-):)),<
M"%60*5BXB"9CDW>"%9\RD)F0P$%C:'JH<P4M*E;+A4[(H3/U];3]!+80LE>(
M+WFUB0Q<!6!RVI%#4C"R"EMS3A6,#"4M17;#*&HSB%;C'<%Z8@#5$/<Y;1#(
MZQ#R\33R08[0IB.=,_AD!(^\8<A@4@MDIDN5\MQP>'@*D#6S,G4^(7!&C"T<
MN-FXD4FYC*_&SF2F?V>\=?XZ:XS[1^=@'"?GY\/^8'#ZX=VO6[M;_/MHV#^N
M?O_M=#!^_^M6=W?W[UM_5H)V8?) <<,7T'5ATHHHCZ^JF:$\9A05U\- XN8'
MXT'UQJV.BSD&=GJO=+9%%<#@\"N/WUY^&-?%;D\E3+/8$R.F%?N"OW3Z=^4W
M!"TAXL0(G@<[-':Y 'G/V>EE&_R"G*0%8\+BIG0 UC7P!\P@G [;N[O=%F=-
M9#]PUBIG U-KD1B9G6H#PV%[H.>+V!IC34'T:J#X5PRF %M1M\'[R\'[BIV!
M6)UZ4A$K(-8G;,1;#7R:1%H?CZ-%%9Z!,(Z4L4A5- >^7"I>3A(373LQ;D<*
MH@&>B9X&<;<]2%.Y"#EA1CF 0K"<JF+!'E)@+U9.=**+!9$K9"Z6\6YO3D2E
MM? P:"G0OBH3])?^$]>]16=14L9JS^M]9WQ%_Q%2G[U@$\Q?_V]>\ W![SF'
M6?>**T7IDR3D0 R$20IC4V1'P.YSB43KB0F7+Q1906FZ.ST9< 1J<U9+S1*8
M 5+@($"P*^T4-0;FFR8R3;T7O8SQ J(R\ FJE'2><?)#X.0D,*\$1#5S]X@7
M)\G,9&UF5#6Z]6S?)YT-?_I:-CQJ]W9_"LDPH>.LMB/;<\ERKU)&KI%43DGG
MJP]EG:::\T7"9"^?&U0IR&71/-"_5K/A<A7I*6D(R\:HD&941-2J:LHWB!4N
M#!$A5]$KN;*1(DDH^&BJ'+"%PLM)$0P%><GS:M ];7TIHY')0 /#SD'VJ 3$
M) G2'Y]*H20.,BU+='"Y64*1BW*L$R^+N4%.CZ$C1V552L%Q6=MC&6MB7ZQ$
ME ^WJX^$!3Y 2$E:$P1UP9EX[A;JH9P*=2YC2!O #1Z2%E"W:C8*AO(I!%0$
M>D!D$UH)'Z=^UN?<_/\1<T\IMA*=Y)-"@*X[N2N=.7M6%4<QUS9>R]8]>EAA
MWK-(KL%]^;3YP.D9&#\$,/IYCL!&*=?8G%A[;,M9"*">905<?.R,.M7GJ;:N
M6,?(L\5_#(N_)3H.LU4'UYP"X,[ 0,I *)VZ[^_O%)U7Y'-DLWYA33X'7:>1
MM;,X/F[ISU3[2B6<+BZD)^\#52M]B;0W&_V+P?9W \PC')=54_VMW19OM4KB
M/3'$EO?Q_N>2,B:FW1>7.1/5/9IW%,[#V^UP47DP./WWZE6?AU>WMP%?O]!W
M$V-C!-GJNZ-$1M>B"XD<BO,84JULK&;U39=D?Q33V.G!#D3=(/4$'.6Z/5$
M"1;*>?_U27_9,"GMKB[I ]>I*TO6E+Q#6O8Z? XE3X7I][[&]"^]SQ^!JY+I
MWJF$>&4XMKH\>A<.K4(MD)H8#)DO2VQ:W1TA\91T<)J;9)$BNLP7,BFM 5EI
M-F2DXQ5^+R,07N;+ZV<%MZ8$7YXK9KX=4;M[G/!!;E0Z5W%B3XI^FH"JRUB#
MX'(P"YOEJ+@,AWPK.3,8V6QP*6+5U$KF_N*:!8E@U\7RJ&YX=;:\1H5H,V5]
MOD5YFT&V(*955%KX6$L"O1WT6^)VKA,D6M0GI!Z2%0E:QOX*$D-K!R4D"VVA
MMX'6K4;RG,HI1Q<T2Q%4C@<JH==C-:6KK&?>__^1[(=6M4\_#$2JB*//5O#U
M539'KH52$\_23<Z!H<!UA>=GZO=CH&'MA#:WAFY6IV3H2.5%:^7D]8%X4AWK
MUL+(O?!Q%W$V%95\)/%=*X9'N2_M3TQ9^"SRU*]&'P]"O-UF@W-U!810]?/I
MEDP*1DJM VAY*UIK>_ '5RF2.0W1O]-W0%]<TC$?7XK2C9(_"EYV1MS=M89#
MMB!'."FD>ZV[D\ '&FOJ)X#^F(P/^_*JLEU-C7<=-A!XAX[#4,W84,TL^VQJ
MU0RU-/F+P(WW?"T^QX:36*-CF8#SI&F9F398#^1G+R/-/.YM8+/!>YE@UVV$
MK2B1SFVX"Z2%ZU>!+)H2030R1>UR<"SNWPI6<O(%89V1&41$K*9\CY693ML%
MX*E0ME"OA)HRP? ;]_>'VKF2;LZ=,Y%F87@'Z_>''7%ZQWY:@<]I5\=9(&RM
M&K-L-OX8M13$+%L/4<M5LK;DE&]AI-1?4] JP>AYPLTPU,?U4*>3;W3BZ/P7
M7NL_2MS#'F^EC=OGQER3CD<$1#KE>_(=(B/C.Q7)\&XIM<])P V=>SNXM;<6
M=7@$=YJ&'2=^Q\&Q4'N0RUBZM@:.\]*Z4F9%=8I.6$;\L1.J%:@IUM6ZX896
MWQ",1O!PZV^YSO%CYAWI2C%$^Q%W.G7?O'G%[27NFP*M;(IY>7V?'+BXP#%P
MB-10=.63'^P^FSE_?E/O?%F/TEXZ.*RQP6']>*MF5?@B_/,E/I=#,J>=4T$1
MQB#8%A)9@X40:QT[(?ZW@NR5_W;)?ZO*BQ8-T;]%U>4MA:$0Y%T)_W3\V2HS
M;?FH@6_G=Y(XDK!ZD1H8J+<3Y9^9D%QP<PKRW+%#G^E*N@"B4,].)-@-/X5>
MDJ0RR(K&;TQ"_9?:77OME&!1O%\V,"6D9H/6C"0=J0%M95+PK0LB$[51I'1V
MYKODIM:DZSAUBIN1."]M0&Q-;YO-ZPU#DH%Q\9.[]E5O:R\M[T"@9.8F#03
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M4$L! A0#%     @ &SQH4U$(EWX-"   76,  !4              ( !0A@
M &MP<G@M,C R,3$Q,#5?<')E+GAM;%!+ 0(4 Q0    ( !L\:%/RFEH#$!<
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H,S(Q,C5D,5]E>#DY+3$N:'1M4$L%!@     (  @ $@(  %^/      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
